Bicycle Therapeutics (BCYC) Current Assets (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Current Assets came in at $575.2 million in Q2 2026, down 28.48% YoY from $804.3 million in Q2 2025, and down 7.09% on a QoQ basis from $619.1 million in Q1 2026.
Bicycle Therapeutics (BCYC) Current Assets (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Current Assets data on file, last reported at $575.2 million in Q2 2026.
- Quarterly Current Assets fell 28.48% year-over-year to $575.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $575.2 million (down 28.48% YoY) and the FY2025 annual result came in at $682.9 million, down 26.46% from the prior year.
- Current Assets eased to $575.2 million in Q2 2026, from $619.1 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.0 billion in Q2 2024 to a low of $369.4 million in Q4 2022.
- A 5-year average of $625.5 million and a median of $589.1 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets jumped 151.76% — and 2026, when it slipped 28.48%.
- Tracing BCYC's Current Assets over 5 years: stood at $369.4 million in 2022, then surged by 52.11% to $561.9 million in 2023, then jumped by 65.27% to $928.6 million in 2024, then retreated by 26.46% to $682.9 million in 2025, then slipped by 15.76% to $575.2 million in 2026.
- The last three Current Assets figures came in at $575.2 million (Q2 2026), $619.1 million (Q1 2026), and $682.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 575.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 575.24 Mn |
| Mar 31, 2026 | 619.14 Mn |
| Dec 31, 2025 | 682.89 Mn |
| Sep 30, 2025 | 738.82 Mn |
| Jun 30, 2025 | 804.26 Mn |
| Mar 31, 2025 | 856.09 Mn |
| Dec 31, 2024 | 928.61 Mn |
| Sep 30, 2024 | 966.19 Mn |
| Jun 30, 2024 | 1.03 Bn |
| Mar 31, 2024 | 515.96 Mn |
| Dec 31, 2023 | 561.87 Mn |
| Sep 30, 2023 | 603.04 Mn |
| Jun 30, 2023 | 408.43 Mn |
| Mar 31, 2023 | 381.25 Mn |
| Dec 31, 2022 | 369.38 Mn |
| Sep 30, 2022 | 381.29 Mn |
| Jun 30, 2022 | 408.49 Mn |
| Mar 31, 2022 | 429.77 Mn |
| Dec 31, 2021 | 458.56 Mn |
| Sep 30, 2021 | 272.87 Mn |